JP2017525955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525955A5 JP2017525955A5 JP2017506291A JP2017506291A JP2017525955A5 JP 2017525955 A5 JP2017525955 A5 JP 2017525955A5 JP 2017506291 A JP2017506291 A JP 2017506291A JP 2017506291 A JP2017506291 A JP 2017506291A JP 2017525955 A5 JP2017525955 A5 JP 2017525955A5
- Authority
- JP
- Japan
- Prior art keywords
- pkd
- patient
- cyclin
- level
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030761 polycystic kidney disease Diseases 0.000 claims 44
- 238000000034 method Methods 0.000 claims 26
- 108050006400 Cyclin Proteins 0.000 claims 17
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 17
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 17
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims 17
- 102000003861 Ribosomal protein S6 Human genes 0.000 claims 13
- 108090000221 Ribosomal protein S6 Proteins 0.000 claims 13
- 108091008611 Protein Kinase B Proteins 0.000 claims 12
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims 12
- 108010023377 Retinoblastoma Binding Proteins Proteins 0.000 claims 12
- 102000011260 Retinoblastoma Binding Proteins Human genes 0.000 claims 12
- 108010058546 Cyclin D1 Proteins 0.000 claims 11
- 108010058545 Cyclin D3 Proteins 0.000 claims 11
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims 11
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims 11
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 9
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims 9
- 210000001124 body fluid Anatomy 0.000 claims 8
- -1 5-fluoro-4- (4-((2-methoxyethoxy) methyl) phenyl) pyrimidin-2-yl Chemical group 0.000 claims 7
- 102000004046 Caspase-2 Human genes 0.000 claims 6
- 108090000552 Caspase-2 Proteins 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- 108091005981 phosphorylated proteins Proteins 0.000 claims 6
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims 5
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 5
- 210000001808 exosome Anatomy 0.000 claims 4
- 210000002700 urine Anatomy 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- NMAHPRBPCRWREJ-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(2-methoxyethoxy)phenyl]pyrimidin-2-yl]-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound FC1(CCN(CC1)C1=NC=CC(=N1)C1=CC=C(C=C1)OCCOC)C(=O)NC1(CCN2CCC1CC2)C NMAHPRBPCRWREJ-UHFFFAOYSA-N 0.000 claims 1
- PXLMHHFXTQNWJZ-UHFFFAOYSA-N 4-fluoro-1-[4-[4-(methoxymethyl)phenyl]pyrimidin-2-yl]-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)piperidine-4-carboxamide Chemical compound FC1(CCN(CC1)C1=NC=CC(=N1)C1=CC=C(C=C1)COC)C(=O)NC1(CCN2CCC1CC2)C PXLMHHFXTQNWJZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- UMWIMNNPYBWNRY-XMMPIXPASA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[4-[4-(2-methoxyethoxy)phenyl]phenyl]propan-2-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC=C(C(C)(C)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 UMWIMNNPYBWNRY-XMMPIXPASA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical group C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033031P | 2014-08-04 | 2014-08-04 | |
| US62/033,031 | 2014-08-04 | ||
| PCT/US2015/043497 WO2016022500A2 (en) | 2014-08-04 | 2015-08-03 | Biomarkers of polycystic kidney disease and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113693A Division JP7005695B2 (ja) | 2014-08-04 | 2020-07-01 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525955A JP2017525955A (ja) | 2017-09-07 |
| JP2017525955A5 true JP2017525955A5 (enExample) | 2018-09-13 |
| JP6730252B2 JP6730252B2 (ja) | 2020-07-29 |
Family
ID=54035292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506291A Active JP6730252B2 (ja) | 2014-08-04 | 2015-08-03 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| JP2020113693A Active JP7005695B2 (ja) | 2014-08-04 | 2020-07-01 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020113693A Active JP7005695B2 (ja) | 2014-08-04 | 2020-07-01 | 多発性嚢胞腎のバイオマーカーおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10871495B2 (enExample) |
| EP (1) | EP3177932B1 (enExample) |
| JP (2) | JP6730252B2 (enExample) |
| KR (1) | KR20170033436A (enExample) |
| CN (1) | CN106716136B (enExample) |
| AU (1) | AU2015301278A1 (enExample) |
| BR (1) | BR112017002003A2 (enExample) |
| CO (1) | CO2017001596A2 (enExample) |
| MX (1) | MX2017001648A (enExample) |
| RU (1) | RU2017106891A (enExample) |
| SG (1) | SG11201700290SA (enExample) |
| WO (1) | WO2016022500A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003500418A (ja) * | 1999-05-24 | 2003-01-07 | エイブイアイ バイオファーマ， インコーポレイテッド | 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス |
| US9006181B2 (en) | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| US20120077263A1 (en) | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102018702B (zh) * | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| US20140079769A1 (en) * | 2010-10-01 | 2014-03-20 | Fabiola Terzi | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| ES2982997T3 (es) | 2012-07-03 | 2024-10-21 | Fond Centro San Raffaele | 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
-
2015
- 2015-08-03 JP JP2017506291A patent/JP6730252B2/ja active Active
- 2015-08-03 AU AU2015301278A patent/AU2015301278A1/en not_active Abandoned
- 2015-08-03 SG SG11201700290SA patent/SG11201700290SA/en unknown
- 2015-08-03 BR BR112017002003A patent/BR112017002003A2/pt not_active Application Discontinuation
- 2015-08-03 WO PCT/US2015/043497 patent/WO2016022500A2/en not_active Ceased
- 2015-08-03 RU RU2017106891A patent/RU2017106891A/ru not_active Application Discontinuation
- 2015-08-03 MX MX2017001648A patent/MX2017001648A/es unknown
- 2015-08-03 KR KR1020177005740A patent/KR20170033436A/ko not_active Withdrawn
- 2015-08-03 EP EP15757363.5A patent/EP3177932B1/en active Active
- 2015-08-03 US US15/501,496 patent/US10871495B2/en active Active
- 2015-08-03 CN CN201580053081.4A patent/CN106716136B/zh active Active
-
2017
- 2017-02-17 CO CONC2017/0001596A patent/CO2017001596A2/es unknown
-
2020
- 2020-07-01 JP JP2020113693A patent/JP7005695B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Negoita et al. | PNPLA3 variant M148 causes resistance to starvation‐mediated lipid droplet autophagy in human hepatocytes | |
| Pan et al. | The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies | |
| Rodrik-Outmezguine et al. | mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling | |
| Janzic et al. | PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung | |
| Alves et al. | PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex | |
| JP2016536303A5 (enExample) | ||
| Boudreau et al. | Molecular signalling pathways in canine gliomas | |
| JP2017525955A5 (enExample) | ||
| Baldelli et al. | Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors | |
| JP2016528914A5 (enExample) | ||
| Park et al. | Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component | |
| Chen et al. | Ser9 phosphorylation of GSK-3β promotes aging in the heart through suppression of autophagy | |
| JP2019502902A5 (enExample) | ||
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| RU2017106891A (ru) | Биомаркеры поликистозной болезни почек и пути их применения | |
| JP6895963B2 (ja) | 多発性嚢胞腎のバイオマーカーおよびその使用 | |
| WO2017086332A1 (ja) | 間葉系ｋｒａｓ変異型がん治療剤 | |
| Brown et al. | Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development | |
| Ochiai et al. | Cerebral phaeohyphomycosis: case report | |
| JP7324769B2 (ja) | 腫瘍細胞中のＲＡＤ５１ ｆｏｃｉの検出に基づく方法 | |
| Pikunov et al. | Personalization of mathematical models of human atrial action potential | |
| Thomas Jr et al. | Phosphatidylinositol kinase regulation of airway smooth muscle cell proliferation | |
| US20040186117A1 (en) | Marker | |
| Eathiraj et al. | Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751 | |
| DEVARASETTI et al. | Assessment of disease activity in Takayasus arteritis using conventional inflammatory markers and it as 2010. Results from a cohort from South-East India: APL15-0639 |